TP53 and breast cancer: In breast cancer, we found prognostic amplifications that were centered around oncogenes, including ERBB2, MYC, and MDM2, while prognostic deletions encompassed tumor suppressors CDKN2A, PTEN, and TP53 (Figure 4G).